Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Work
Year: 2019
Type: article
Abstract: Purpose In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy i... more
Source: Journal of Clinical Oncology
Institutions: LungenClinic Grosshansdorf, Hospital Universitario Insular de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Kingston General Hospital, The University of Sydney +14 more
Language: English
Cites: 22
Cited by: 1,492
Related to: 10
FWCI: 112.3
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal: Good health and well-being
Open Access status: green